New 13D21
New 13G62
Stated intents0
The week of 2026-10-13, 21 holders filed a new Schedule 13D and 62 a new Schedule 13G reporting 5% or more of a company, and 0 13D filings stated in Item 4 an intent to influence the company. Open a company for every holder and the purpose each 13D states, quoted.
New Schedule 13D
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2026-10-16 | AI OKTO Corp. | Pani Corp. | 74.2% | SCHEDULE 13D |
| 2026-10-14 | Dreamland Ltd | Seto Wai Yue | 53.15% | SCHEDULE 13D |
| 2026-10-13 | Bradbury Capital Inc. | Loo See Yuen | 52.66% | SCHEDULE 13D |
| 2026-10-13 | Canagold Resources Ltd. | Sun Valley Investments AG | 49.8% | SCHEDULE 13D |
| 2026-10-13 | Pine Tree Acquisition Corp. | Pine Tree Sponsor Group, LLC | 32.7% | SCHEDULE 13D |
| 2026-10-15 | Gogoro Inc. | Ruen Hua Dyeing & Weaving Co., Ltd. | 21.92% | SCHEDULE 13D |
| 2026-10-16 | Linkhome Holdings Inc. | Qin Zhen | 20.14% | SCHEDULE 13D |
| 2026-10-15 | Alaunos Therapeutics, Inc. | Fairmount Funds Management LLC | 19.99% | SCHEDULE 13D |
| 2026-10-16 | TRex Bio, Inc. | ELI LILLY & Co | 19.9% | SCHEDULE 13D |
| 2026-10-13 | Integer Holdings Corporation | Tarheel Investors III L.P. | 14% | SCHEDULE 13D |
| 2026-10-13 | Borr Drilling Limited | Drew Holdings Ltd. | 12.2% | SCHEDULE 13D |
| 2026-10-13 | Powerus Corp | Michael Sinensky | 11.6% | SCHEDULE 13D |
| 2026-10-14 | MDA Space Ltd. | Mariselle A.S. | 9.5% | SCHEDULE 13D |
| 2026-10-14 | TROOPS, Inc. | Prime Ocean Holdings Limited | 9% | SCHEDULE 13D |
| 2026-10-13 | Powerus Corp | Roman Vintfeld | 8.9% | SCHEDULE 13D |
| 2026-10-14 | Retension Pharmaceuticals, Inc. | Eric Keller | 7.07% | SCHEDULE 13D |
| 2026-10-16 | TRex Bio, Inc. | SV Biotech Crossover Opportunities Fund LP | 7% | SCHEDULE 13D |
| 2026-10-14 | Franklin Street Properties Corp. | Powell Anderson Capital Partners LLC | 6.8% | SCHEDULE 13D |
| 2026-10-15 | Strata Critical Medical, Inc. | Third Point LLC | 5.8% | SCHEDULE 13D |
| 2026-10-14 | BlackRock TCP Capital Corp. | Saba Capital Management, L.P. | 5.11% | SCHEDULE 13D |
| 2026-10-15 | Maxcyte, Inc. | Liontrust Investment Partners LLP | 5% | SCHEDULE 13D |
New Schedule 13G
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2026-10-13 | Churchill Direct Lending Fund | Teachers Insurance and Annuity Association of America | 100% | SCHEDULE 13G |
| 2026-10-16 | Linkhome Holdings Inc. | Qin Zhen | 31.24% | SCHEDULE 13G |
| 2026-10-15 | Exascale Labs Holdings Inc. | ARC Group International Limited | 14.7% | SCHEDULE 13G |
| 2026-10-15 | DevvStream Corp. | Helena Global Investment Opportunities 1 Ltd. | 14.07% | SCHEDULE 13G |
| 2026-10-15 | DarkIris Inc. | Orca Capital AG | 11.7% | SCHEDULE 13G |
| 2026-10-16 | ADARx Pharmaceuticals, Inc. | Yi Shi | 11.1% | SCHEDULE 13G |
| 2026-10-16 | Retension Pharmaceuticals, Inc. | The B Group, Inc. | 10% | SCHEDULE 13G |
| 2026-10-13 | DarkIris Inc. | L1 Capital Global Opportunities Master Fund, Ltd. | 9.99% | SCHEDULE 13G |
| 2026-10-13 | DarkIris Inc. | S.H.N. Financial Investments Ltd. | 9.99% | SCHEDULE 13G |
| 2026-10-13 | Merlin, Inc. | Inflection Point Fund I, LP | 9.9% | SCHEDULE 13G |
| 2026-10-13 | Sunshine Biopharma Inc. | CVI Investments, Inc. | 9.9% | SCHEDULE 13G |
| 2026-10-13 | Solowin Holdings, Ltd. | Streeterville Capital LLC | 9.9% | SCHEDULE 13G |
| 2026-10-15 | Evernorth Holdings Inc. | Larsen Christian A | 9.9% | SCHEDULE 13G |
| 2026-10-15 | China SXT Pharmaceuticals, Inc. | Orca Capital AG | 9.9% | SCHEDULE 13G |
| 2026-10-14 | iBio, Inc. | Coastlands Capital LP | 9.72% | SCHEDULE 13G |
| 2026-10-13 | Outlook Therapeutics, Inc. | Empery Asset Management, LP | 8.73% | SCHEDULE 13G |
| 2026-10-14 | IRulya Therapeutics Inc. | Perceptive Advisors LLC | 8.4% | SCHEDULE 13G |
| 2026-10-15 | Dyadic International Inc. | Empery Asset Management, LP | 8.35% | SCHEDULE 13G |
| 2026-10-16 | Retension Pharmaceuticals, Inc. | Pvg Asset Management Corp | 8.3% | SCHEDULE 13G |
| 2026-10-13 | Vicore Pharma Holding AB | HBM Healthcare Investments (Cayman) Ltd. | 8% | SCHEDULE 13G |
| 2026-10-13 | Pine Tree Acquisition Corp. | CVI Investments, Inc. | 7.6% | SCHEDULE 13G |
| 2026-10-15 | Fuelcell Energy Inc | Alex Meruelo | 7.5% | SCHEDULE 13G |
| 2026-10-15 | Retension Pharmaceuticals, Inc. | Laurence W. Lytton | 7.4% | SCHEDULE 13G |
| 2026-10-13 | HubSpot, Inc. | Jpmorgan Chase & Co. | 7.3% | SCHEDULE 13G |
| 2026-10-16 | TRex Bio, Inc. | Pfizer Inc. (13-5315170) | 7.2% | SCHEDULE 13G |
| 2026-10-15 | newcleo plc | Buono Stefano | 7.1% | SCHEDULE 13G |
| 2026-10-16 | VEON Ltd. | Himanshu H. Shah | 6.72% | SCHEDULE 13G |
| 2026-10-16 | Novavax, Inc. | Himanshu H. Shah | 6.46% | SCHEDULE 13G |
| 2026-10-16 | Frazier Life Sciences Acquisition Corp. II | Coastlands Capital LP | 6.41% | SCHEDULE 13G |
| 2026-10-13 | U S Physical Therapy Inc | Copeland Capital Management, LLC | 6.3% | SCHEDULE 13G |
| 2026-10-13 | Excelerate Energy, Inc. | Copeland Capital Management, LLC | 6.1% | SCHEDULE 13G |
| 2026-10-16 | Weave Communications Inc | Glazer Capital, LLC | 6.1% | SCHEDULE 13G |
| 2026-10-14 | IRulya Therapeutics Inc. | James B. Tananbaum | 6% | SCHEDULE 13G |
| 2026-10-14 | Skye Bioscience, Inc. | Tang Capital Management, LLC | 6% | SCHEDULE 13G |
| 2026-10-14 | Sunshine Biopharma Inc. | BJI Financial Group | 6% | SCHEDULE 13G |
| 2026-10-13 | Napco Security Technologies, Inc | Copeland Capital Management, LLC | 5.8% | SCHEDULE 13G |
| 2026-10-13 | Knight-Swift Transportation Holdings Inc. | SteelMill Master Fund LP | 5.7% | SCHEDULE 13G |
| 2026-10-13 | Veradermics, Inc | Jpmorgan Chase & Co. | 5.6% | SCHEDULE 13G |
| 2026-10-13 | Fractyl Health, Inc. | Catalio Capital Management, LP | 5.6% | SCHEDULE 13G |
| 2026-10-15 | Femasys Inc. | Empery Asset Management, LP | 5.6% | SCHEDULE 13G |
| 2026-10-16 | Pasqal Holding SA | Temasek Holdings (Private) Limited | 5.6% | SCHEDULE 13G |
| 2026-10-16 | Blend Labs, Inc. | Capricorn Fund Managers Ltd | 5.6% | SCHEDULE 13G |
| 2026-10-16 | Belpointe PREP, LLC | Donnalley David James | 5.6% | SCHEDULE 13G |
| 2026-10-13 | Lexeo Therapeutics, Inc. | Jpmorgan Chase & Co. | 5.5% | SCHEDULE 13G |
| 2026-10-13 | Surgery Partners, Inc. | Glenview Capital Management, LLC | 5.4% | SCHEDULE 13G |
| 2026-10-15 | newcleo plc | Simon Fiduciaria S.p.A. | 5.4% | SCHEDULE 13G |
| 2026-10-16 | Netcapital Inc. | Jane Street Group, LLC | 5.4% | SCHEDULE 13G |
| 2026-10-13 | REGENXBIO Inc. | Jpmorgan Chase & Co. | 5.3% | SCHEDULE 13G |
| 2026-10-15 | TRex Bio, Inc. | Johnson & Johnson Innovation - JJDC, Inc. | 5.3% | SCHEDULE 13G |
| 2026-10-13 | Helix Acquisition Corp. III | Sculptor Capital LP | 5.23% | SCHEDULE 13G |
| 2026-10-13 | Silence Therapeutics plc | Tetragon Financial Group Limited | 5.2% | SCHEDULE 13G |
| 2026-10-15 | Atour Lifestyle Holdings Limited | M&G Plc on behalf of certain subsidiaries | 5.2% | SCHEDULE 13G |
| 2026-10-15 | Protalix BioTherapeutics, Inc. | HOLD Alapkezelo Zrt. | 5.2% | SCHEDULE 13G |
| 2026-10-13 | Lantronix, Inc. | Portolan Capital Management, LLC | 5.15% | SCHEDULE 13G |
| 2026-10-16 | Global Water Resources, Inc. | TSP Capital Management Group, LLC | 5.11% | SCHEDULE 13G |
| 2026-10-13 | Rhythm Pharmaceuticals, Inc. | Jpmorgan Chase & Co. | 5.1% | SCHEDULE 13G |
| 2026-10-13 | YETI Holdings, Inc. | Reinhart Partners, LLC. | 5.1% | SCHEDULE 13G |
| 2026-10-16 | Sweetgreen, Inc. | D. E. Shaw & Co., L.P. | 5.1% | SCHEDULE 13G |
| 2026-10-13 | H World Group Limited | Jpmorgan Chase & Co. | 5% | SCHEDULE 13G |
| 2026-10-13 | ArriVent BioPharma, Inc. | Vivo Opportunity, LLC | 5% | SCHEDULE 13G |
| 2026-10-13 | Aethlon Medical Inc | Jane Street Group, LLC | 5% | SCHEDULE 13G |
| 2026-10-15 | First Solar, Inc. | Citadel Securities GP LLC | 5% | SCHEDULE 13G |
Stated intent
No 13D this week stated an intent to influence the company.
Download this data (CSV)83 rows, with sources
Tools for this story
Each opens in a new tab. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.